Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Onyx

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Onyx's 2012 oncology sales performance.

Onyx Pharmaceuticals, Inc.

Europe backs two blood cancer treatments

Europe backs two blood cancer treatments The drug is already available in the US under the name Pomalyst, where it was approved shortly after rival late-stage multiple myeloma treatment Onyx Pharmaceuticals' Kyprolis (carfilzomib).

Onyx rejects $10bn takeover bid from Amgen

Onyx rejects $10bn takeover bid from Amgen Cancer specialist Onyx Pharmaceuticals has rejected a $10bn unsolicited takeover offer from biopharma giant Amgen as being too low, but said it may consider a sale of the business. ... For example, Bayer and Onyx have just filed in the US and Europe to

Elotuzumab on track for multiple myeloma

Elotuzumab on track for multiple myeloma and other drugs such as Onyx/Ono's Kyprolis (carfilzomib) and Takeda/Millennium's MLN9708 each grabbing a share of the combination market.

FDA turns down tivozanib for kidney cancer

FDA turns down tivozanib for kidney cancer based on a review of several studies including the TIVO-1 trial, which compared tivozanib to Bayer/ Onyx Pharmaceuticals' already-marketed Nexavar (sorafenib).

EMA backs Pomalidomide Celgene in multiple myeloma

EMA backs Pomalidomide Celgene in multiple myeloma past 12 months; the other being Kyprolis (carfilzomib) from Onyx Pharmaceuticals.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...